Epigenica

Executive Summary

Epigenica, a Swedish epigenetics company founded in 2016, specializes in innovative epigenetic analysis tools to advance human health. Its flagship product, EpiFinder™ cNUC, is a live, direct multiplex epigenomic assay designed for liquid biopsy. This technology enables comprehensive epigenomic profiling from blood samples, offering insights into disease biology without invasive procedures. By providing a holistic view of epigenetic modifications, EpiFinder™ cNUC aims to accelerate research and clinical applications in oncology and other fields. Despite limited public information on funding or pipeline, Epigenica's focus on liquid biopsy epigenomics positions it in a rapidly growing market. The company's platform has potential for diagnostics and drug development partnerships. With its product already live, Epigenica may seek commercial traction or strategic alliances. The absence of disclosed milestones or partnerships suggests an early stage, but the technology's novelty warrants attention. Future catalysts could include validation studies, collaborations, or fundraising to scale operations.

Upcoming Catalysts (preview)

• Q4 2026Publication of clinical validation data for EpiFinder™ cNUC40% success
• H2 2026Strategic partnership or licensing agreement with a diagnostic or pharma company30% success
• 2027Series A funding round to support commercialization and expansion50% success